Allergan, Medicines360 launch single-handed IUD inserter LILETTA

Allergan and Medicines360 have teamed up to launch the Liletta, a 52 mg IUD single-handed inserter.

Liletta received FDA approval in January and is meant for pregnancy prevention in women for up to three years. In a previous clinical trial of 1,751 women, the IUD inserter was used in women and was found to be 99.5 percent effective in preventing pregnancy. Liletta can be used in women regardless of their BMI and can be inserted the same day as a clinic visits. The insertion success rate with the single-handed device was 99.2 percent. Liletta can be used as both a long- and short-term contraception.

"We are excited to bring to market the new Liletta inserter and anticipate that the single-handed process may lead to broader use by healthcare providers, thereby increasing the number of women who have access to this effective contraceptive," said Jessica Grossman, MD, CEO of  Medicines360. "Specifically, the new Liletta inserter includes an ergonomic design allowing for single-handed insertion that can be used with either hand, a bendable tube to accommodate the anatomy of the patient during insertion; and the ability to reload the device if needed before insertion."